These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31707701)

  • 21. Harnessing allostery: a novel approach to drug discovery.
    Lu S; Li S; Zhang J
    Med Res Rev; 2014 Nov; 34(6):1242-85. PubMed ID: 24827416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic discovery of molecular probes targeting multiple non-orthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A).
    Dadgar S; Floriano WB
    Mol Cell Probes; 2015 Jun; 29(3):135-43. PubMed ID: 25745992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASD v2.0: updated content and novel features focusing on allosteric regulation.
    Huang Z; Mou L; Shen Q; Lu S; Li C; Liu X; Wang G; Li S; Geng L; Liu Y; Wu J; Chen G; Zhang J
    Nucleic Acids Res; 2014 Jan; 42(Database issue):D510-6. PubMed ID: 24293647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of receptor allosterism.
    Gregory KJ; Sexton PM; Christopoulos A
    Curr Protoc Pharmacol; 2010 Dec; Chapter 1():Unit 1.21. PubMed ID: 21935895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response.
    Tee WV; Guarnera E; Berezovsky IN
    PLoS Comput Biol; 2018 Jun; 14(6):e1006228. PubMed ID: 29912863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Ascaris suum nicotinic receptor, ACR-16, as a drug target: Four novel negative allosteric modulators from virtual screening.
    Zheng F; Robertson AP; Abongwa M; Yu EW; Martin RJ
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):60-73. PubMed ID: 27054065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric Modulators of Protein-Protein Interactions (PPIs).
    Ni D; Liu N; Sheng C
    Adv Exp Med Biol; 2019; 1163():313-334. PubMed ID: 31707709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coupling dynamics and evolutionary information with structure to identify protein regulatory and functional binding sites.
    Mishra SK; Kandoi G; Jernigan RL
    Proteins; 2019 Oct; 87(10):850-868. PubMed ID: 31141211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computer-aided drug-discovery techniques that account for receptor flexibility.
    Durrant JD; McCammon JA
    Curr Opin Pharmacol; 2010 Dec; 10(6):770-4. PubMed ID: 20888294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development.
    Luo ML; Zhao Q; He XH; Xie X; Zhu HP; You FM; Peng C; Zhan G; Huang W
    Biomed Pharmacother; 2023 Jun; 162():114574. PubMed ID: 36996677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.
    Sabatucci A; Tortolani D; Dainese E; Maccarrone M
    Biotechnol Appl Biochem; 2018 Jan; 65(1):21-28. PubMed ID: 28833445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks.
    Szilágyi A; Nussinov R; Csermely P
    Curr Top Med Chem; 2013; 13(1):64-77. PubMed ID: 23409766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.
    Brust R; Lin H; Fuhrmann J; Asteian A; Kamenecka TM; Kojetin DJ
    ACS Chem Biol; 2017 Apr; 12(4):969-978. PubMed ID: 28165718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational allosteric ligand binding site identification on Ras proteins.
    McCarthy M; Prakash P; Gorfe AA
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):3-10. PubMed ID: 26487442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward Comprehensive Allosteric Control over Protein Activity.
    Guarnera E; Berezovsky IN
    Structure; 2019 May; 27(5):866-878.e1. PubMed ID: 30827842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allostery and Missense Mutations as Intermittently Linked Promising Aspects of Modern Computational Drug Discovery.
    Tastan Bishop Ö; Musyoka TM; Barozi V
    J Mol Biol; 2022 Sep; 434(17):167610. PubMed ID: 35490897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allosteric sites can be identified based on the residue-residue interaction energy difference.
    Ma X; Qi Y; Lai L
    Proteins; 2015 Aug; 83(8):1375-84. PubMed ID: 25185787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
    Redka DS; Pisterzi LF; Wells JW
    Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
    Feng Z; Hu G; Ma S; Xie XQ
    AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The different ways through which specificity works in orthosteric and allosteric drugs.
    Nussinov R; Tsai CJ
    Curr Pharm Des; 2012; 18(9):1311-6. PubMed ID: 22316155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.